Inventiva S.A. 2025 Q4 - Results - Earnings Call Presentation

Inventiva S.A. released its Q4 2025 earnings presentation during a March 2026 earnings call, detailing financial performance and strategic updates for the biopharma company. The slide deck, published alongside the call, provides quarterly revenue figures, R&D milestones, and pipeline progress, though specific financial metrics were not disclosed in the transcript summary. Key focus areas include clinical trial advancements for lead drug candidates, with potential regulatory submissions expected in 2026 based on prior guidance. Operational highlights emphasize cost optimization and partnerships, reflecting broader industry trends in biotech funding and collaboration strategies. The presentation underscores Inventiva’s long-term growth strategy, prioritizing rare disease therapies and precision medicine amid evolving market conditions.